Information on various Biotech Venture Capital Firms

Here is some information about different European Biotechnology Venture Capital Funds for those interested in raising capital for healthcare related opportunities.

BlueCrest Capital Finance, L.P. (USA)

BlueCrest Capital Finance, L.P., a US based commercial finance company, provides debt financing solutions to development stage companies in a broad range of industry sectors including IT, Communications, Hardware, Software, Semi-Conductor, Electronics, Energy, Medical Device and Life Science. Environmental, infrastructure and cleantech opportunities are also being provided. Financing range typically starts from $1m.

CVC Capital Partners (Asia & Europe)

CVC Capital Partners is one of the world’s leading private equity and investment advisory firms. Founded in 1981, CVC today employs some 250 people throughout Europe, Asia and the US.

The fund invests in mid to late stage businesses – for its European funds, the target minimum equity investment is US$150 million. For Asian funds, the minimum equity investment is US$50 million.

Crest Capital Asia (Asia based)

Crest Capital Asia is a specialized alternative investment firm that focuses in investment opportunities around under-served, mid-capitalization regional enterprises. 

With mainly Asian investor institutions, government agencies and family offices as clients, it identifies investment opportunities in the region with proven business models and, in particular, those which had built intellectual properties or proprietary franchises.

Some of its medical related investments include medical equipment services, medical product distributors, e-health and cosmetic surgery products.

Javelin Ventures (UK based)

Javelin Ventures is a UK based venture capital fun, it operates a biotechnology focused fund called Heptagon Fund with 7 partners which include UK’s most reputable medical colleges, which include Queen Mary, University of London, King’s College London University of Kent, The Royal Veterinary College, The School of Pharmacy, and St George’s Hospital Medical School.

The Heptagon Fund provides proof of concept funding for its seven partners for new technologies in life sciences and healthcare. The Fund addresses the translation of novel and inventive ideas from fundamental research to commercial demonstration, leading to soundly based propositions able to attract licensing deals or investment funding. 

VI Partners (Switzerland)

VI Partners is a Swiss venture capital firm that supports university spin-off's as well as other promising start-up companies with capital, coaching, consulting and networks. 

Via its current "Venture Incubator" fund VI Partners invests money to develop promising technology-based ideas for products and services into successful businesses. 

Venture Incubator was established by McKinsey & Company and the Swiss Federal Institute of Technology in Zürich (ETHZ), and started operations in 2001. It now manages an investment fund of CHF 101 million.

Its life science portfolio include various companies at different stages, Activaero is the global technology leader in controlled breathing technologies for inhaled therapeutics. CeQur, CeQur is a spin off of Danfoss Bionics and develops fast acting insulin “dumb pumps”. Edimer is a biotech company based in Epalinges (VD and Boston (US) focusing on the development of innovative therapeutics for rare diseases.

Forbion Capital Partners (The Netherlands)

The Forbion team is specialized in the evaluation of late stage preclinical / early stage clinical development programs. It focuses on companies that have innovative technologies and drug development programs with unique advantages over current treatments. 

It invests in medical device companies with a focus on interventional cardiology and gastroenterology.  

Current portfolio includes companies in various stages including: Amakem (European company), a platform company focusing on ophthalmology and is developing new treatments for serious eye conditions. Argos (US company) – which develops treatment of metastatic cancers and chronic infections using a proprietary platform technology, involving stimulating immune cells with messenger RNA. 

Forbion Capital Partners is a global investor, with its portfolio consisting American, Canadian and European (including UK) companies. 

Looking for Biotechnology & Health Venture Capital Investors?

Global Biotechnology Capital Providers Guide

Check out our Global Biotechnology Capital Providers Guide which includes various investors from Americas, Asia and Europe, they invest in diverse range of investors at different stages. 

Please visit our website http://researchwhitepaper.com

Please Click Here For More Information